Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma.
复制标题
走出黑暗，走向光明：明场原位杂交用于描绘乳腺癌中 ERBB2 (HER2) 的状态。
DOI：
10.1136/jcp.2009.062760
复制
发表时间：
2010
影响因子：
3.4
通讯作者：
Tubbs,RaymondR
中科院分区：
文献类型：
--
作者：
Gruver,AaronM;Peerwani,Ziad;Tubbs,RaymondR
Assessment ofERBB2(HER2)status in breast carcinomas has become critical in determining response to the humanised monoclonal antibody trastuzumab. The current joint College of American Pathologists and the American Society of Clinical Oncology guidelines for the evaluation ofHER2status in breast carcinoma involve testing by immunohistochemistry and fluorescence in situ hybridisation (FISH). However, neither of these modalities is without limitations. Novel bright field in situ hybridisation techniques continue to provide viable alternatives to FISH testing. While these techniques are not limited to evaluation of theHER2gene, the extensive number of studies comparing bright field in situ techniques with other methods of assessingHER2status allow a robust evaluation of this approach. Analysis of the literature demonstrates that, when used to assessHER2gene status, bright field in situ hybridisation demonstrates excellent concordance with FISH results. The average percentage agreement in an informal analysis of studies comparingHER2amplification by chromogenic in situ hybridisation with FISH was 96% (SD 4%); κ coefficients ranged from 0.76 to 1.0. Although a much smaller number of studies are available for review, similar levels of concordance have been reported in studies comparingHER2amplification by methods employing metallography (silver in situ hybridisation) with FISH. A summary of the advancements in bright field in situ hybridisation, with focus on those techniques with clinical applications of interest to the practicing pathologist, is presented.
